Cargando…
Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
Cardiovascular disease (CVD), the number one cause of death worldwide, has always been the focus of clinical and scientific research. Due to the high number of deaths each year, it is essential to find alternative therapies that are safe and effective with minimal side effects. Traditional Chinese m...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507407/ https://www.ncbi.nlm.nih.gov/pubmed/32982178 http://dx.doi.org/10.2147/DDDT.S272355 |
_version_ | 1783585221569937408 |
---|---|
author | Tan, Yu-Qing Chen, Heng-Wen Li, Jun |
author_facet | Tan, Yu-Qing Chen, Heng-Wen Li, Jun |
author_sort | Tan, Yu-Qing |
collection | PubMed |
description | Cardiovascular disease (CVD), the number one cause of death worldwide, has always been the focus of clinical and scientific research. Due to the high number of deaths each year, it is essential to find alternative therapies that are safe and effective with minimal side effects. Traditional Chinese medicine (TCM) has a long history of significant impact on the treatment of CVDs. The mode of action of natural active ingredients of drugs and the development of new drugs are currently hot topics in research on TCM. Astragalus membranaceus is a commonly used Chinese medicinal herb. Previous studies have shown that Astragalus membranaceus has anti-tumor properties and can regulate metabolism, enhance immunity, and strengthen the heart. Astragaloside IV (AS-IV) is the active ingredient of Astragalus membranaceus, which has a prominent role in cardiovascular diseases. AS-IV can protect against ischemic and hypoxic myocardial cell injury, inhibit myocardial hypertrophy and myocardial fibrosis, enhance myocardial contractility, improve diastolic dysfunction, alleviate vascular endothelial dysfunction, and promote angiogenesis. It can also regulate blood glucose and blood lipid levels and reduce the risk of cardiovascular diseases. In this paper, the mechanism of AS-IV intervention in cardiovascular diseases in recent years is reviewed in order to provide a reference for future research and new drug development. |
format | Online Article Text |
id | pubmed-7507407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75074072020-09-24 Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases Tan, Yu-Qing Chen, Heng-Wen Li, Jun Drug Des Devel Ther Review Cardiovascular disease (CVD), the number one cause of death worldwide, has always been the focus of clinical and scientific research. Due to the high number of deaths each year, it is essential to find alternative therapies that are safe and effective with minimal side effects. Traditional Chinese medicine (TCM) has a long history of significant impact on the treatment of CVDs. The mode of action of natural active ingredients of drugs and the development of new drugs are currently hot topics in research on TCM. Astragalus membranaceus is a commonly used Chinese medicinal herb. Previous studies have shown that Astragalus membranaceus has anti-tumor properties and can regulate metabolism, enhance immunity, and strengthen the heart. Astragaloside IV (AS-IV) is the active ingredient of Astragalus membranaceus, which has a prominent role in cardiovascular diseases. AS-IV can protect against ischemic and hypoxic myocardial cell injury, inhibit myocardial hypertrophy and myocardial fibrosis, enhance myocardial contractility, improve diastolic dysfunction, alleviate vascular endothelial dysfunction, and promote angiogenesis. It can also regulate blood glucose and blood lipid levels and reduce the risk of cardiovascular diseases. In this paper, the mechanism of AS-IV intervention in cardiovascular diseases in recent years is reviewed in order to provide a reference for future research and new drug development. Dove 2020-09-15 /pmc/articles/PMC7507407/ /pubmed/32982178 http://dx.doi.org/10.2147/DDDT.S272355 Text en © 2020 Tan et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Tan, Yu-Qing Chen, Heng-Wen Li, Jun Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases |
title | Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases |
title_full | Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases |
title_fullStr | Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases |
title_full_unstemmed | Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases |
title_short | Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases |
title_sort | astragaloside iv: an effective drug for the treatment of cardiovascular diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507407/ https://www.ncbi.nlm.nih.gov/pubmed/32982178 http://dx.doi.org/10.2147/DDDT.S272355 |
work_keys_str_mv | AT tanyuqing astragalosideivaneffectivedrugforthetreatmentofcardiovasculardiseases AT chenhengwen astragalosideivaneffectivedrugforthetreatmentofcardiovasculardiseases AT lijun astragalosideivaneffectivedrugforthetreatmentofcardiovasculardiseases |